ERT has announced the acquisition of APDM Wearable Technologies (APDM, Inc.), a provider of wearables and digital biomarkers. The combined company will aim to generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient.
Current clinical trial assessments in movement disorders such as Parkinson’s disease (PD), Multiple Sclerosis (MS), and Ataxia are subjective and based on episodic visits. Consequently, drug development decisions in Central Nervous System (CNS) and other pathologies result in large-scale trials that are costly and highly unpredictable. APDM’s wearable platform is designed to address these challenges by providing precision motion data collected with medical-grade wearable sensors and digital endpoints to guide critical decision-making and allow for more objective, efficient, and effective evaluation of therapies.
“We are thrilled that our advanced wearable platform will be added to ERT’s suite of proven eClinical technologies to help innovative clinical trial sponsors minimize uncertainty and risk in the development of CNS and movement disorder treatments, ultimately improving patients’ lives,” said Dr. Mateo Aboy, Co- Founder & Chairman of APDM.
As an example, by integrating Patient Reported Outcomes (PRO) data captured by ERT’s eCOA platform with data from APDM’s wearables and digital endpoints, trial sponsors gain insights and comprehensive safety and efficacy data as they develop new medical treatments for many therapies including movement-related disorders. The integrated solution can be used to support in-clinic assessments as well as in trials conducted virtually.
“To truly understand a new drug’s effect on movement disorders, sponsors need objective, real-world data that can only be captured by a medical-grade precision motion device and combined with traditional clinical endpoints for a complete view on efficacy,” said James Corrigan, President, and CEO of ERT. “APDM’s advanced technology and broad understanding of objective precision movement measurement complements ERT’s expertise in high-quality clinical trial data collection, delivering the most efficient and effective approach for trial sponsors developing new medical treatments for the millions of patients living with movement disorders today.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.